Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno
N
N
Campiglio
M
M
Perrone
F
F
De Luca
A
A
Menard
S
S
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D000077156:Gefitinib; D006801:Humans; D018579:Patient Selection; D011799:Quinazolines / Q000008:administration & dosage; D015203:Reproducibility of Results; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011799:Quinazolines; D000068878:Trastuzumab; D000077156:Gefitinib